JPH0144718B2 - - Google Patents

Info

Publication number
JPH0144718B2
JPH0144718B2 JP13400487A JP13400487A JPH0144718B2 JP H0144718 B2 JPH0144718 B2 JP H0144718B2 JP 13400487 A JP13400487 A JP 13400487A JP 13400487 A JP13400487 A JP 13400487A JP H0144718 B2 JPH0144718 B2 JP H0144718B2
Authority
JP
Japan
Prior art keywords
ethyl
dihydroquinoline
oxo
fluoro
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP13400487A
Other languages
Japanese (ja)
Other versions
JPS62294689A (en
Inventor
Toshihiro Fujiwara
Hideaki Tsurumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP13400487A priority Critical patent/JPS62294689A/en
Publication of JPS62294689A publication Critical patent/JPS62294689A/en
Publication of JPH0144718B2 publication Critical patent/JPH0144718B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はキノリン―3―カルボン酸誘導体に関
する。更に詳しくは、本発明は式 (式中、R1は低級アルキル基を、X1及びX2
同じ又は異なるハロゲン原子を意味する。)で表
わされる化合物に関する。 この化合物は、医療上有用な抗菌物質として知
られているノルフロキサシン(特開昭53―141286
号及び特開昭54―138582号公報参照)等の製造中
間体して有用である。ノルフロキサシンの製造法
としては前記公報及び特開昭57―62259号公報に
記載されている製造法がある。 しかし、これらの製造法を用いた場合、ピペラ
ジン類がキノリン誘導体の6位に置換した式 (式中、R1及びX2は前記に同じであり、R2
びR3は水素原子又は低級アルキル基を意味す
る。)で表わされる化合物が少なからず副生する
という欠点がある。 前記特開昭57―62259号公報には化合物()
のような副生物は全く見られないとの記載がある
が、本発明者らがこの製造法を追試したところ、
得られた生成物中には約25%の副生物()が存
在することが判明した。 本発明者らは鋭意検討した結果、式()で表
わされる化合物を出発原料とすることにより、上
記の欠点を克服できることを見出し本発明を完成
した。 化合物()は次の方法により製造される。 (式中、X1,X2及びR1は前記に同じであり、
R4は水素原子又は低級アルキル基を意味する。) 即ち、化合物()に三フツ化ホウ素、三フツ
化ホウ素錯体又はホウフツ化水素酸を反応させる
ことにより化合物()を得ることができる。 三フツ化ホウ素錯体としては各種のものが使用
可能であるが、三フツ化ホウ素のテトラヒドロフ
ラン錯体及びジエチルエーテル錯体等が具体例と
してあげられる。又、ホウフツ化水素酸は通常水
溶液として使用される。 三フツ化ホウ素、三フツ化ホウ素錯体又はホウ
フツ化水素酸の使用量は化合物()1モルに対
し1モル以上存在すればよいが通常1〜50モルの
範囲が使用される。 溶媒としてはアセトン等のケトン系のもの、ジ
エチルエーテル等のエーテル系のもの、ベンゼン
又はトルエン等各種のものが使用でき、又、三フ
ツ化ホウ素錯体もしくはホウフツ化水素酸を溶媒
と兼ねさせてもよい。溶媒の使用量は通常化合物
()1部に対し2〜50部の範囲が好適である。 反応温度は室温でもよいが、反応時間の短縮と
いうことから更に高温でもよく、通常室温〜150
℃の温度範囲が好適である。 生成した化合物()は反応液を冷却すれば結
晶とて析出するので、これを濾取することにより
容易に得ることができる。 化合物()に一乃至数倍モルのピペラジンを
無溶媒で又は溶媒中、脱酸剤の存在下反応させれ
ばノルフロキサシンが生成する。 脱酸剤は、副生するハロゲン化水素及びBF2
キレート分解物の除去に使用され、その具体例と
してはトリエチルアミン、トリブチルアミンもし
くはピリジンの如き有機三級アミン又は炭酸カリ
ウムの如き無機塩基があげられるが、過剰のピペ
ラジンが脱酸剤として働くこともある。脱酸剤の
使用量は化合物()1モルに対し通常1〜3モ
ルが好ましい。 この反応ではBF2―キレート部分がカルボキシ
ル基となるためにプロトンが必要とされるが、、
これは過剰の原料又は混在する微量の水分等によ
り供給されることが考えられる。 溶媒としては、ジメチルスルホキシド、ジメチ
ルホルムアミドもしくはジメチルアセトアミド等
の非プロトン性極性溶媒、アセトンもしくはメチ
ルエチルケトン等のケトン系溶媒、ジエチルエー
テルもしくはジオキサン等のエーテル系溶媒、酢
酸エチル等のエステル系溶媒又はメタノールもし
くはエタノール等のアルコール系溶媒等が使用で
きる。溶媒の使用量は化合物()1部に対し2
〜30部(重量比)の範囲で使用される。反応は室
温〜200℃の範囲で2〜10時間行えばよい。 尚、該反応においては溶媒の種類を選択し、脱
酸剤の使用量、反応温度及び反応時間等を調節す
ることにより、ピペラジン類の置換反応の段階で
反応を止め、式 (式中、R1,R2及びX1は前記に同じである。)
で表わされる中間体を得ることも可能である。例
えば、ジメチルスルホキシド中室温で反応を行つ
た場合、中間体()が収率よく得られる。 中間体()は、反応液を冷却するか、反応液
に水等の難溶性の溶媒を加えることにより析出す
るので、これを濾取することにより容易に単離で
きる。 中間体()は単離してもよいが、単離せずに
次のキレート分解反応を行つてもつい。 中間体()よりノルフロキサシン類を得るに
は、中間体()を脱酸剤の存在下無溶媒もしく
は溶媒中プロトン性の化合物と処理すればよい。
プロトン性化合物としては水、アルコール類、チ
オール類、一級アミン類、二級アミン類又は無機
水酸化物等が使用される。 脱酸剤としては水酸化ナトリウム、炭酸ナトリ
ウムもしくは炭酸水素ナトリウム等の無機塩基又
は一級アミン、二級アミンもしきは三級アミン等
の有機塩基があげられ、中間体()に対し等モ
ル以上使用される。 溶媒としては非プロトン性極性溶媒、ケトン系
溶媒、アルコール系溶媒、エステル系溶媒又はエ
ーテル系溶媒等が、特にアルコール系溶媒、エス
テル系溶媒又はエーテル系溶媒が好ましい。反応
は室温〜150℃の範囲で行えばよい。 生成したノルフロキサシン類は、反応液を中和
するか又は冷却すれば結晶として析出するので、
これを濾取することにより容易に得ることができ
る。 実施例 1 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸エチルエステル2.93g及びホウフツ化水素酸
42%水溶液15mlの混液を80〜90℃で3時間加熱す
る。冷後析出晶を濾取し、水及びメタノールで洗
浄し、7―クロロ―1―エチル―6―フルオロ―
4―オキソ―1,4―ジヒドロキノリン―3―カ
ルボン酸―BF2―キレート3.10g(収率99%)を
得た。融点300℃以上。 元素分析値 C12H8NO3BClF3として 計算値 C45.40,H2.54,N4.41 実測値 C45.21,H2.61,N4.421 H―NMR(DMSO―d6,IS:TMS)δ
(ppm):1.49(3H,t,―CH3)4.95(2H,
q,―CH2)8.53(1H,d,J=10Hz,5
位=CH―)8.88(1H,d,J=6Hz),8
位=CH―)9.64(1H,s,2位=CH―)
Nass:317(M+) 実施例 2 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸エチルエステル5.35g、三フツ化ホウ素テト
ラヒドロフラン錯体12.7g及びダウサム21mlの混
液を120〜130℃で2時間加熱する。冷後析出晶を
濾取し、クロロホルム及びメタノールで洗浄し、
7―クロロ―1―エチル―6―フルオロ―4―オ
キソ―1,4―ジヒドロキノリン―3―カルボン
酸―BF2―キレート4.67g(収率82%)を得た。
融点300℃以上。 実施例 3 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸4.30g及びホウフツ化水素酸42%水溶液21ml
の混液を80〜90℃で2時間加熱する。冷後析出晶
を濾取し、水及びメタノールで洗浄し、7―クロ
ロ―1―エチル―6―フルオロ―4―オキソ―
1,4―ジヒドロキノリン―3―カルボン酸―
BF2―キレート5.10g(収率100%)を得た。融
点300℃以上。 実施例 4 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸1.66g及び三フツ化ホウ素テトラヒドロフラ
ン錯体17mlの混液を80〜90℃で8時間加熱する。
冷後析出晶を濾取し、クロロホルムで洗浄し、7
―クロロ―1―エチル―6―フルオロ―4―オキ
ソ―1,4―ジヒドロキノリン―3―カルボン酸
―BF2―キレート1.68g(収率86%)を得た。融
点300℃以上。 参考例 1 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸―BF2―キレート1.000g、無水ピペラジン
0.814g及びジメチルスルホキシド5mlの混液を
室温下6時間撹拌する。反応液はいつたん溶液と
なるが、1時間経過すると結晶が析出する。反応
後、冷水5mlを加え結晶を濾取し、水洗し、90℃
で5時間減圧乾燥し、1―エチル―6―フルオロ
―4―オキソ―7―(1―ピペラジニル)―1,
4―ジヒドロキノリン―3―カルボン酸―BF2
キレート1.113g(収率96%)を得た。融点253〜
255℃。 元素分析値 C16H17N3O3BF3として 計算値 C52.34,H4.67,N11.45 実測値 C52.46,H4.56,N11.321 H―NMR(DMSO―d6,IS:TMS)δ
(ppm):1.49(3H,t,―CH3)3.3〜3.4
(8H,m,
The present invention relates to quinoline-3-carboxylic acid derivatives. More specifically, the invention relates to the formula (In the formula, R 1 represents a lower alkyl group, and X 1 and X 2 represent the same or different halogen atoms.) This compound is known as a medically useful antibacterial substance, norfloxacin (Japanese Patent Laid-Open No. 53-141286).
It is useful as an intermediate for the production of products such as JP-A-54-138582). Examples of the production method for norfloxacin include those described in the above-mentioned publication and Japanese Patent Application Laid-Open No. 57-62259. However, when these production methods are used, the formula in which piperazine is substituted at the 6-position of the quinoline derivative (In the formula, R 1 and X 2 are the same as above, and R 2 and R 3 mean a hydrogen atom or a lower alkyl group.) There is a drawback that a considerable amount of the compound represented by the formula is produced as a by-product. The compound (
Although it is stated that no by-products such as
Approximately 25% by-products () were found to be present in the product obtained. As a result of extensive studies, the present inventors have found that the above drawbacks can be overcome by using the compound represented by formula () as a starting material, and have completed the present invention. Compound () is produced by the following method. (In the formula, X 1 , X 2 and R 1 are the same as above,
R 4 means a hydrogen atom or a lower alkyl group. ) That is, compound () can be obtained by reacting compound () with boron trifluoride, a boron trifluoride complex, or hydroborofluoric acid. Various types of boron trifluoride complexes can be used, and specific examples include tetrahydrofuran complexes and diethyl ether complexes of boron trifluoride. Further, hydroborofluoric acid is usually used in the form of an aqueous solution. The amount of boron trifluoride, boron trifluoride complex or hydroborofluoric acid to be used should be 1 mol or more per 1 mol of the compound (), but it is usually in the range of 1 to 50 mol. As the solvent, various solvents such as ketones such as acetone, ethers such as diethyl ether, benzene or toluene can be used, and boron trifluoride complexes or hydroborofluoric acid may also be used as the solvent. good. The amount of solvent to be used is usually preferably in the range of 2 to 50 parts per 1 part of compound (). The reaction temperature may be at room temperature, but it may also be at a higher temperature to shorten the reaction time, usually between room temperature and 150°C.
A temperature range of 0.degree. C. is preferred. The produced compound () precipitates as crystals when the reaction solution is cooled, and can be easily obtained by filtering the crystals. Norfloxacin is produced by reacting compound () with one to several moles of piperazine in the absence of a solvent or in a solvent in the presence of a deoxidizing agent. The deoxidizing agent is a by-product of hydrogen halide and BF 2 -
Used to remove chelate decomposition products, examples include organic tertiary amines such as triethylamine, tributylamine or pyridine, or inorganic bases such as potassium carbonate, although excess piperazine may act as a deoxidizing agent. . The amount of the deoxidizing agent used is usually preferably 1 to 3 mol per 1 mol of the compound (). In this reaction, a proton is required for the BF 2 -chelate moiety to become a carboxyl group.
It is thought that this is supplied by excess raw materials or a trace amount of moisture mixed therein. Examples of solvents include aprotic polar solvents such as dimethyl sulfoxide, dimethylformamide, or dimethylacetamide, ketone solvents such as acetone or methyl ethyl ketone, ether solvents such as diethyl ether or dioxane, ester solvents such as ethyl acetate, or methanol or ethanol. Alcohol-based solvents such as, etc. can be used. The amount of solvent used is 2 parts per part of the compound ().
~30 parts (weight ratio) is used. The reaction may be carried out at room temperature to 200°C for 2 to 10 hours. In addition, in this reaction, by selecting the type of solvent and adjusting the amount of deoxidizer used, reaction temperature, reaction time, etc., the reaction can be stopped at the stage of the piperazine substitution reaction, and the formula (In the formula, R 1 , R 2 and X 1 are the same as above.)
It is also possible to obtain intermediates of the form: For example, when the reaction is carried out in dimethyl sulfoxide at room temperature, intermediate () can be obtained in good yield. The intermediate () precipitates by cooling the reaction solution or adding a poorly soluble solvent such as water to the reaction solution, and can be easily isolated by filtering it. The intermediate () may be isolated, but may also be subjected to the next chelate decomposition reaction without being isolated. In order to obtain norfloxacins from intermediate (), intermediate () may be treated with a protic compound in the presence of a deoxidizer or in a solvent without a solvent.
As the protic compound, water, alcohols, thiols, primary amines, secondary amines, or inorganic hydroxides are used. Examples of deoxidizers include inorganic bases such as sodium hydroxide, sodium carbonate, or sodium hydrogen carbonate, or organic bases such as primary amines, secondary amines, or tertiary amines, and are used in an amount equal to or more than the amount of the intermediate (). be done. Examples of the solvent include aprotic polar solvents, ketone solvents, alcohol solvents, ester solvents, and ether solvents, with alcohol solvents, ester solvents, and ether solvents being particularly preferred. The reaction may be carried out at room temperature to 150°C. The generated norfloxacins will precipitate as crystals if the reaction solution is neutralized or cooled.
It can be easily obtained by filtering it. Example 1 7-chloro-1-ethyl-6-fluoro-4-
2.93 g of oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester and hydroborofluoric acid
A mixture of 15 ml of 42% aqueous solution is heated at 80-90°C for 3 hours. After cooling, the precipitated crystals were collected by filtration, washed with water and methanol, and 7-chloro-1-ethyl-6-fluoro-
3.10 g (yield 99%) of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate was obtained. Melting point over 300℃. Elemental analysis value C 12 H 8 NO 3 As BClF 3 Calculated value C45.40, H2.54, N4.41 Actual value C45.21, H2.61, N4.42 1 H―NMR (DMSO―d 6 , IS: TMS)δ
(ppm): 1.49 (3H, t, - CH 3 ) 4.95 (2H,
q, - CH 2 ) 8.53 (1H, d, J = 10Hz, 5
position = CH-) 8.88 (1H, d, J = 6Hz), 8
Place = CH-) 9.64 (1H, s, 2nd place = CH-)
Nass: 317 (M + ) Example 2 7-chloro-1-ethyl-6-fluoro-4-
A mixture of 5.35 g of oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester, 12.7 g of boron trifluoride tetrahydrofuran complex, and 21 ml of Dowsum is heated at 120 to 130°C for 2 hours. After cooling, the precipitated crystals were collected by filtration, washed with chloroform and methanol,
4.67 g (yield: 82%) of 7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate was obtained.
Melting point over 300℃. Example 3 7-chloro-1-ethyl-6-fluoro-4-
4.30 g of oxo-1,4-dihydroquinoline-3-carboxylic acid and 21 ml of 42% aqueous solution of hydroborofluoric acid
Heat the mixture at 80-90°C for 2 hours. After cooling, the precipitated crystals were collected by filtration, washed with water and methanol, and 7-chloro-1-ethyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid-
5.10 g (yield 100%) of BF 2 -chelate was obtained. Melting point over 300℃. Example 4 7-chloro-1-ethyl-6-fluoro-4-
A mixture of 1.66 g of oxo-1,4-dihydroquinoline-3-carboxylic acid and 17 ml of boron trifluoride tetrahydrofuran complex is heated at 80-90°C for 8 hours.
After cooling, the precipitated crystals were collected by filtration and washed with chloroform.
1.68 g (yield: 86%) of -chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate was obtained. Melting point over 300℃. Reference example 1 7-chloro-1-ethyl-6-fluoro-4-
Oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate 1.000g, anhydrous piperazine
A mixture of 0.814 g and 5 ml of dimethyl sulfoxide was stirred at room temperature for 6 hours. The reaction solution quickly becomes a solution, but crystals precipitate after one hour. After the reaction, add 5 ml of cold water, collect the crystals by filtration, wash with water, and heat at 90°C.
and dried under reduced pressure for 5 hours to obtain 1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,
4-dihydroquinoline-3-carboxylic acid-BF 2 -
1.113 g (yield 96%) of chelate was obtained. Melting point 253~
255℃. Elemental analysis value C 16 H 17 N 3 O 3 BF 3 Calculated value C52.34, H4.67, N11.45 Actual value C52.46, H4.56, N11.32 1 H―NMR (DMSO―d 6 , IS:TMS)δ
(ppm): 1.49 (3H, t, - CH 3 ) 3.3-3.4
(8H, m,

【式】)4.87(2H, q,―CH2 ―CH3)7.35(1H,d,J=8
Hz,8位=CH―)8.09(1H,d,J=14
Hz,5位=CH―)9.04(1H,s,2位=
CH―)Mass:367(M+) 上記化合物1.113g及び6%水酸化ナトリウム
水溶液8.9mlの混液を1時間還流した。反応液を
酢酸で中和して、PH7〜7.5に調整する。冷後、
析出する結晶を濾取し、水及びメタノールで洗浄
する。これをクロロホルムとエタノールの混合溶
液から再結晶し、90℃で5時間減圧乾燥し、1―
エチル―6―フルオロ―4―オキソ―7―(1―
(ピペラジニル)―1,4―ジヒドロキノリン―
3―カルボン酸0.904g(収率93%)を得た。融
点221〜222℃。 元素分析値 C16H18N3O3Fとして 計算値 C60.18,H5.68,N13.16 実測値 C60.15,H5.74,N13.27 本品は特開昭53―141286号公報の方法に従つて
合成した標品と混融しても融点降下を示さず、赤
外線吸収スペクトルも完全に一致した。 参考例 2 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸―BF2―キレート1.000g、無水ピペラジン
0.814g及びジメチルスルホキシド5mlの混液を
100℃で3時間加熱する。次いで6%水酸化ナト
リウム水溶液8mlを加え、120℃で2時間加熱し
た。反応液に酢酸を加え、PH7〜7.5に調整し、
析出する結晶を濾取し、水及びメタノールで洗浄
する。クロロホルムとエタノールの混合溶液で再
結晶し、90℃で5時間減圧乾燥し、1―エチル―
6―フルオロ―4―オキソ―7―(1―ピペラジ
ニル)―1,4―ジヒドロキノリン―3―カルボ
ン酸0.861g(収率86%)を得た。融点220〜221
℃。 参考例 3 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸―BF2―キレート567mg、無水ピペラジン630
mg及びジメチルスルホキシド2.8mlの混液を110℃
で3時間加熱した。反応液に水10mlを加え、更に
酢酸を加え、PH7.5に調整する。冷後、析出晶を
濾取し水洗する。これをクロロホルムとエタノー
ルの混合溶液で再結晶し、90℃で5時間減圧乾燥
し、1―エチル―6―フルオロ―4―オキソ―7
―(1―ピペラジニル)―1,4―ジヒドロキノ
リン―3―カルボン酸419mg(収率73%)を得た。
融点220〜221℃。 参考例 4 7―クロロ―1―エチル―6―フルオロ―4―
オキソ―1,4―ジヒドロキノリン―3―カルボ
ン酸―BF2―キレート726mg、4―メチルピペラ
ジン687mg及びジメチルスルホキシド3.6mlの混液
を110℃で3時間加熱した。反応液に6%水酸化
ナトリウム水溶液5.8mlを加え、110℃で2時間加
熱した。反応終了後、酢酸を反応液に加え、PH7
〜7.5に調整する。冷後、析出する結晶を濾取す
る。メタノールで洗浄し、90℃で5時間減圧乾燥
し、1―エチル―6―フルオロ―7―(4―メチ
ル―1―ピペラジニル)―4―オキソ―1,4―
ジヒドロキノリン―3―カルボン酸653mg(収率
86%)を得た。融点268〜270℃。 元素分析値 C17H20N3O3Fとして 計算値 C61.25,H6.05,N12.60 実測値 C61.10,H5.91,N12.27
[Formula]) 4.87 (2H, q, -C H 2 - CH 3 ) 7.35 (1H, d, J = 8
Hz, 8th place = CH-) 8.09 (1H, d, J = 14
Hz, 5th place = CH-) 9.04 (1H, s, 2nd place =
CH-) Mass: 367 (M + ) A mixture of 1.113 g of the above compound and 8.9 ml of a 6% aqueous sodium hydroxide solution was refluxed for 1 hour. Neutralize the reaction solution with acetic acid and adjust the pH to 7-7.5. After cooling,
The precipitated crystals are collected by filtration and washed with water and methanol. This was recrystallized from a mixed solution of chloroform and ethanol, dried under reduced pressure at 90°C for 5 hours, and 1-
Ethyl-6-fluoro-4-oxo-7-(1-
(piperazinyl)-1,4-dihydroquinoline-
0.904 g (yield 93%) of 3-carboxylic acid was obtained. Melting point 221-222℃. Elemental analysis value C 16 H 18 N 3 O 3 F Calculated value C60.18, H5.68, N13.16 Actual value C60.15, H5.74, N13.27 This product is published in JP-A-53-141286 Even when it was mixed with the standard product synthesized according to the method of 2009, no drop in melting point was observed, and the infrared absorption spectrum completely matched. Reference example 2 7-chloro-1-ethyl-6-fluoro-4-
Oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate 1.000g, anhydrous piperazine
A mixture of 0.814g and 5ml of dimethyl sulfoxide
Heat at 100℃ for 3 hours. Then, 8 ml of 6% aqueous sodium hydroxide solution was added and heated at 120°C for 2 hours. Add acetic acid to the reaction solution and adjust the pH to 7 to 7.5.
The precipitated crystals are collected by filtration and washed with water and methanol. Recrystallize from a mixed solution of chloroform and ethanol, dry under reduced pressure at 90°C for 5 hours, and obtain 1-ethyl-
0.861 g (yield: 86%) of 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxylic acid was obtained. Melting point 220-221
℃. Reference example 3 7-chloro-1-ethyl-6-fluoro-4-
Oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate 567 mg, anhydrous piperazine 630
A mixture of mg and 2.8 ml of dimethyl sulfoxide was heated to 110°C.
It was heated for 3 hours. Add 10 ml of water to the reaction solution, and then add acetic acid to adjust the pH to 7.5. After cooling, the precipitated crystals are collected by filtration and washed with water. This was recrystallized from a mixed solution of chloroform and ethanol, dried under reduced pressure at 90°C for 5 hours, and 1-ethyl-6-fluoro-4-oxo-7
419 mg (yield 73%) of -(1-piperazinyl)-1,4-dihydroquinoline-3-carboxylic acid was obtained.
Melting point 220-221℃. Reference example 4 7-chloro-1-ethyl-6-fluoro-4-
A mixture of 726 mg of oxo-1,4-dihydroquinoline-3-carboxylic acid-BF 2 -chelate, 687 mg of 4-methylpiperazine and 3.6 ml of dimethyl sulfoxide was heated at 110° C. for 3 hours. 5.8 ml of 6% aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was heated at 110°C for 2 hours. After the reaction is complete, add acetic acid to the reaction solution to adjust the pH to 7.
Adjust to ~7.5. After cooling, precipitated crystals are collected by filtration. Washed with methanol and dried under reduced pressure at 90°C for 5 hours to obtain 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-
Dihydroquinoline-3-carboxylic acid 653 mg (yield
86%). Melting point 268-270℃. Elemental analysis value C 17 H 20 N 3 O 3 F Calculated value C61.25, H6.05, N12.60 Actual value C61.10, H5.91, N12.27

Claims (1)

【特許請求の範囲】 1 式 (式中、X1及びX2は同じ又は異なるハロゲン
原子を、R1は低級アルキル基を意味する。)で表
わされる化合物。 2 特許請求の範囲第1項においてR1がエチル
基、X1がフツ素原子X2が塩素原子である化合物。
[Claims] 1 formula (In the formula, X 1 and X 2 are the same or different halogen atoms, and R 1 is a lower alkyl group.) 2. A compound according to claim 1, wherein R 1 is an ethyl group, X 1 is a fluorine atom, and X 2 is a chlorine atom.
JP13400487A 1987-05-29 1987-05-29 Quinoline-3-carboxylic acid derivative Granted JPS62294689A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13400487A JPS62294689A (en) 1987-05-29 1987-05-29 Quinoline-3-carboxylic acid derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13400487A JPS62294689A (en) 1987-05-29 1987-05-29 Quinoline-3-carboxylic acid derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP23368482A Division JPS59122470A (en) 1982-12-27 1982-12-27 Preparation of quinoline-3-carboxylic acid derivative

Publications (2)

Publication Number Publication Date
JPS62294689A JPS62294689A (en) 1987-12-22
JPH0144718B2 true JPH0144718B2 (en) 1989-09-29

Family

ID=15118127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13400487A Granted JPS62294689A (en) 1987-05-29 1987-05-29 Quinoline-3-carboxylic acid derivative

Country Status (1)

Country Link
JP (1) JPS62294689A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46451B (en) * 1987-04-08 1993-10-20 Chinoin Gyogyszer Es Vegyeszeti Ter Mekek Gyara Rt. PROCESS FOR PREPARATION OF MIXED ANHYDRIDS OF QUINOLINE-CARBOXYL AND BORIC ACID
US5380845A (en) * 1987-06-24 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Process for the preparation of quinoline carboxylic acid derivatives

Also Published As

Publication number Publication date
JPS62294689A (en) 1987-12-22

Similar Documents

Publication Publication Date Title
HU215429B (en) Process for producing ((6,7-substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolin-carboxylic acid)-0 upper 3, 0 upper 4-bis(acyl-oxy)-borate and salts
JPH0240066B2 (en)
HU187356B (en) Process for producing quinoline-carboxylic acid derivatives
JP2693988B2 (en) Method for producing quinoline carboxylic acid derivative
KR940008287B1 (en) Process for preparation of quinoline carboxylic acids
DK175037B1 (en) Process for the preparation of quinoline carboxylic acid derivatives and intermediates which may be used in the process
JPH0144718B2 (en)
JPH0717608B2 (en) 6-alkoxyquinolonecarboxylic acid derivative
CA2199645C (en) Methods for the manufacture of quinolone carboxylic acids derivatives and intermediates thereof
JP2005097116A (en) Alkali metal salt of quinolinecarboxylic acid derivative and method of purifying quinolinecarboxylic acid derivative using the same
JPS63179856A (en) Production of quinolonecarboxylic acid derivative and intermediate thereof
KR950011411B1 (en) Method for the preparation of pyridine-2,3-dicarboxylic acids
FI86420C (en) FOERFARANDE FOER FRAMSTAELLNING AV 1-METHYLAMINOQUINOLINE-CARBOXYL SYRADERIVAT.
US5166354A (en) Quinoline derivatives and processes for the preparation thereof
JP2726653B2 (en) Diaminopyrimidine derivative
RU2127270C1 (en) Method of synthesis of 1-substituted-6-fluoro-4-oxo-7-(1- -piperazinyl)-1,4-dihydroquinoline-3-carboxylic acid, 1-substituted-6-fluoro-4-oxo-7-(4-substituted-1-piperazinyl)- -1,4-dihydroquinoline-3-carboxylate-boron-diacetate and a method of its synthesis
JP2990903B2 (en) Production of 4-oxoquinoliine-3-carboxylic acids
RU2002744C1 (en) Method of synthesis of 1-substituted 6-fluoro-4-oxo-7-(1- piperazinyl)-1,4- -dihydroquinoline-3-carboxylic acid
CS265229B2 (en) Making of intermediate for amifloxacine production
JPH0148910B2 (en)
KR900004878B1 (en) Process for preparing of quinoline derivatives
JPS606684A (en) 7-homopiperazine-substituted-6,8-difluoro-4-oxo-1,4- hydroquinoline-3-carboxylic acid derivative
JPH0150709B2 (en)
PL165452B1 (en) Method of obtaining novel quinollinic salt
RU2049783C1 (en) Method of synthesis of quinoline carboxylic acid derivatives or their pharmaceutically acceptable salts